Background. Many studies have suggested clinical benefits of icodextrin in peritoneal dialysis (PD) patients regarding fluid management, glycaemic control and metabolic improvement. However, reports on whether icodextrin can improve patient and technique survival is sparse. Methods. A total of 2163 patients from 54 centres in Korea who initiated PD from July 2003 to December 2006 were enrolled. Outcomes data were retrieved retrospectively from the Baxter Korea database. Among these patients, 641 patients who had been prescribed icodextrin for >50% of their PD duration were defined as the 'icodextrin' group and the remaining 1522 patients as the 'non-icodextrin' group. Propensity score matching yielded 640 matched pairs of patients. We compared all-cause mortality and technique failure rates between the two groups.
Introduction
Over the last few decades, there has been growing concern regarding the deleterious effects of glucose-based peritoneal dialysis (PD) solutions on the peritoneal membrane [1] in spite of a general acceptance of PD as a viable modality in treating patients with end-stage renal disease (ESRD). Since the early 1990s, icodextrin, a glucose polymer derived from starch, has been used as an alternative osmotic agent to glucose for the long dwell in patients undergoing PD. A number of studies have reported that icodextrin solution provides various clinical benefits compared with conventional glucose-based solutions [2] [3] [4] [5] [6] [7] [8] . Thus, it is well known that the use of icodextrin facilitates fluid management and improves fluid status in PD patients [2] , particularly in patients with fluid overload [6] [7] [8] . In addition, as this solution is characterized by normal osmolality, absence of glucose and only very low levels of glucose degradation products (GDPs), it is more biocompatible than conventional glucose-based solutions [3] . Consequently, it is beneficial for managing dyslipidaemia and improves glycaemic control in diabetic patients undergoing PD [9] [10] [11] [12] [13] . However, despite such clinical benefits of icodextrin solution, there have only been a few studies evaluating whether this solution can improve patient and technique survival. Data from a previous Japanese study showed that icodextrin use was significantly associated with a lower mortality and dropout rate compared with patients using glucosebased solutions only [14] . However, that study was limited by its retrospective design and absence of adjustment for comorbidities and other factors. Recently, we showed that treatment with a physiologic pH, bicarbonate/lactate-buffered (B/L) solution was associated with superior survival over conventional solution [15] . Interestingly, in that study, icodextrin solution use was also found to be independently associated with a lower risk of death. However, the primary purpose of that study was not to evaluate the effects of icodextrin and technique failure was not included as a study outcome. Therefore, the present study was conducted to investigate whether icodextrin solution use may confer patient and technique survival advantages in PD patients.
Materials and methods
We conducted a post-hoc analysis using the Baxter Korea database that was utilized in our previous study [15] . In summary, this study included 2311 incident ESRD patients from 54 PD centers in Korea who commenced PD using Baxter solutions between July 2003 and December 2006. These patients were prescribed either B/L (Physioneal Ò ; Baxter Healthcare Corporation, Singapore) or conventional (Dianeal Ò ; Baxter Healthcare Corporation) solutions. We excluded 148 patients who were <18 years old or had experienced more than two changes of PD solution (PDS) during the study period. The latter represented a small group of patients who changed from the original solution, but later, switched back to the initial solution. Therefore, a total of 2163 were included in the final analysis. Using this database, we retrospectively collected demographic, clinical and outcomes data, including age, gender, underlying renal disease, cardiovascular comorbidity, residual urine output and type of PDS at initiation of PD (B/L or conventional), duration of icodextrin (Extraneal Ò ; Baxter Healthcare Corporation) use, follow-up duration, reason for dropout and cause of death. The data including reason for dropout and cause of death were verified by the responsible PD centre staff and were recorded by the clinical co-ordinators employed by Baxter Korea. Icodextrin users were defined as utilization of this solution for >50% of their PD duration. Cardiovascular comorbidity was defined as a history of coronary, cerebrovascular or peripheral vascular disease; coronary disease as a history of angioplasty, coronary artery bypass graft, myocardial infarction or angina; cerebrovascular disease as a previous transient ischaemic attack, stroke or carotid endarterectomy and peripheral vascular disease as a history of claudication, ischaemic limb loss and/or ulceration or a peripheral revascularization procedure. Technique failure was defined as a permanent transfer to haemodialysis (HD) due to peritonitis, ultrafiltration failure (UF), inadequate dialysis, exit and tunnel infection, mechanical problems or non-compliance. The latter was defined as non-adherence to the PD prescription, most frequently related to missed exchanges, accompanied by inadequate dialysis and/or fluid overload. UF was defined as fluid overload associated with inadequate ultrafiltration volume after repeated use of 4.25% glucose solution, which was not related to dietary indiscretion or other non-membrane-related cause, such as heart failure or hernia, i.e. most cases met the recommended UF definition of an ultrafiltration volume <400 mL after 4.25% dialysate dwell in a modified peritoneal equilibration test [16] .
Definition of 'less experienced' centres and 'low socioeconomic status (SES)' were in line with that of our previous study, i.e. the former was defined as centers that had fewer than 40 PD patients and the latter as patients with an income less than US $5 500 per year, unable to work for a living, and living in rented, i.e. not owned, housing.
The closing date of the study was 30 September 2007. We compared all-cause mortality and technique failure between patients treated with and those not treated with icodextrin.
Statistical analysis
Statistical analysis was carried out using SPSS for Windows software, version 13.0 (SPSS Inc, Chicago, Illinois, USA). All data were expressed as mean AE SD. The Student's t-test and the chi-square test were used to compare continuous normally distributed data and categorical variables, respectively. In the patient survival analysis, data for transfer to HD or renal transplantation, transfer to another centre and loss to follow-up were censored. Patients who died within the first 3 months after transferring to HD or receiving a kidney graft were considered as death related to PD. Death, switch to renal transplantation and loss to follow-up were censored for the technique survival analysis. Patients who died due to peritonitis-induced sepsis were, however, considered as representing deaths related to technique failure. We conducted Kaplan-Meier survival analyses to determine patient and technique survival rates and compared these between the icodextrin-and the non-icodextrin group with the use of log-rank tests. A multivariate Cox proportional hazards model adjusted for age at PD initiation, gender, diabetes, cardiovascular comorbidity, SES, centre experience and types of PDS was utilized to identify factors predicting patient mortality and to estimate and test the hazard ratio and the associated 95% confidence intervals (CI). We tested violation of the proportional hazards assumption by means of inspection of log [Àlog (survival)] curves and examination of a time-dependent Cox regression model in which treatment was considered as a time-dependent variable. All probabilities were two tailed and the level of significance was set at 0.05.
To minimize potential confounding and treatment selection bias, rigorous adjustment for significant differences in baseline covariates was performed with the use of propensity score (PS) matching. We used multiple logistic regression analysis to determine the PS for the icodextrin and the non-icodextrin group without considering outcome. All available covariates were included in creating this model. With the use of the Greedy 5/1 digit match algorithm [17] , PS-matched pairs were created without replacement (a 1:1 match). More specifically, each patient using icodextrin solution was matched to a patient not using icodextrin solution and who had a PS that was identical to five digits. If this could not be done, we then proceeded sequentially to the next highest digit PS match (a 4-, 3-, 2-or 1-digit match) to create the best possible matches. After all PS matches were performed, we assessed the balance in baseline covariates between the two groups by using paired t-test for continuous variables and the McNemar test for categorical variables. PS matching was conducted using SAS, version 9.1 (SAS Institute, Cary, NC). Table 1 details the baseline characteristics of the study population. The mean age at the start of PD was 54.9 AE 13.6 years and 53.3% were male. Mean follow-up duration of PD was 23.7 AE 12.4 months with a range of 3.1-50.3 months.
Results

Patient characteristics and comparison of baseline covariates
Of all patients, 641 met the criterion for the icodextrin group, while the remaining 1522 were categorized as belonging to the non-icodextrin group. The mean duration of icodextrin use was 18.0 AE 9.3 (2.0-46.4) months (average 75.8% of total PD duration) in the former and 2.0 AE 4.2 (0-23.3) months (average 7.8% of total PD duration) in the latter (P < 0.001). In the non-icodextrin group, 907 (59.6%) patients had never used icodextrin solution and the remaining 615 patients used this solution at least 1 day. In this unmatched cohort, there were significant differences in underlying renal diseases, use of B/L solution and SES between the two groups ( Table 1) . Compared with the non-icodextrin group, there were more patients with diabetes (63.7 versus 48.7%, P < 0.001), low SES (32.3 versus 23.4%, P < 0.01) and use of B/L solution (32.1 versus 22.1%, P < 0.001) in the icodextrin group. These unbalanced conditions at baseline between the two groups were controlled by using a PS matching. The PS matching yielded 640 matched pairs of patients, resulting in no significant differences in age, gender, diabetics, cardiovascular comorbidity, SES, use of B/L solution or center experience between the two groups ( Table 2 ). In this matched cohort, 74 patients (5.8%) were treated with automated PD (APD): 45 (7.0%) in the icodextrin group and 29 (4.5%) in the non-icodextrin group (data not shown), a difference which was not statistically significant.
Patient outcomes-mortality
In the matched cohort, all-cause deaths occurred in 92 (14.4%) patients in the icodextrin group compared with 128 (20.0%) in the non-icodextrin group (P ¼ 0.006, Table 3 ). In addition, a Kaplan-Meier plot confirmed that all-cause mortality was significantly lower in patients using the icodextrin solution (P ¼ 0.004, Figure 1 ). Twoand four-year patient mortality rates were 14.2% and 26.4% in the icodextrin group and 20.0% (P ¼ 0.004) and 31.1% (P ¼ 0.004) in the non-icodextrin group, respectively. In a multivariate Cox analysis adjusted for age, gender, diabetes, cardiovascular comorbidity, types of PDS (B/L or conventional), SES and center experience, icodextrin use was associated with a significantly lower risk of death (HR, 0.69; 95% CI, 0.53-0.90; P ¼ 0.006, Table 4 ). Because there was a substantial portion of patients who used both icodextrin and B/L solution, we tested an interaction between the two solutions by using a Cox proportional hazard model. When the interaction Table 1 . Baseline characteristics of the study patients (unmatched cohort) term was included, no significant interaction was observed between the two solutions (P ¼ 0.520, data not shown). Furthermore, we conducted a sensitivity analysis in 804 patients for whom data on residual urine output were available. There was no significant difference in residual urine output at initiation of PD between the two matched groups [608.5 AE 418.4 mL/day in the icodextrin group (n ¼ 381) versus 612.3 AE 414.9 mL/day in the non-icodextrin group (n ¼ 423), P ¼ 0.898]. Even after adjustment for residual urine output, the survival benefit of icodextrin remained significant (HR, 0.63; 95% CI, 0.45 to 0.90; P ¼ 0.011, data not shown). Cardiovascular death was the most common cause of mortality (64.8%), followed by infectious death (24.6%). Other causes of death included advanced liver disease (1.8%), malignancy (1.4%) and malnutrition (0.9%). The reason for death was not available in some patients (6.5%). Overall, there was no difference in cause of death between the two matched groups. Although cardiovascular mortality was lower in patients using icodextrin solution, it did not reach statistical significance (P ¼ 0.072, Figure 1 ). In the multivariate Cox analysis, icodextrin solution use was associated with a tendency towards decreased risk of cardiovascular mortality although it was not statistically significant (HR, 0.76; 95% CI, 0.54-1.05; P ¼ 0.098) ( Table 3) . Infection-related mortality rate was not different between the two groups (P ¼ 0.204, Figure 1 ).
Patient outcomes-technique failure
As shown in Table 5 , technique failure occurred in 36 (5.6%) patients in the icodextrin group compared with 56 (8.8%) in the non-icodextrin group (P ¼ 0.030). A KaplanMeier plot confirmed that, compared with the non-icodextrin group, technique failure rate was, indeed, significantly lower in patients using icodextrin solution (P ¼ 0.018, Figure 1 ). In the multivariate Cox analysis, icodextrin use was significantly associated with a decreased risk of technique failure (HR, 0.60; 95% CI, 0.40-0.92; P ¼ 0.018, Table 4 ).
We also evaluated causes of technique failure in this cohort. Peritonitis was the most common cause of technique failure (46.7%) followed by non-compliance and UF. Interestingly, the icodextrin group had significantly fewer technique failures due to non-compliance compared with the non-icodextrin group (0.6% versus 2.0%, P ¼ 0.048), whereas peritonitis-and UF-related technique failures were not different between the two groups ( Table 5 ).
Discussion
In this study, we retrospectively evaluated clinical outcomes of PD patients, and our findings suggest that longterm utilization of icodextrin solution may confer patient and technique survival advantage in PD patients, as the all-cause mortality rate (HR 0.69) and technique failure (HR 0.60) was significantly lower in this group of patients.
To date, there has been only one study suggesting a patient survival advantage of icodextrin solution in PD patients. Kuriyama et al. [14] reported that, regardless of PD vintage, the relative risk of death and dropout were consistently lower in icodextrin users than in patients prescribed glucose solutions only. However, this study was limited by its retrospective design, uncontrolled covariates and absence of adjustment for comorbidities and other important factors that might have affected clinical outcomes. To minimize such limitation, we performed rigorous adjustment for significant differences in baseline covariates by using PS matching in the present study.
Data potentially explaining the survival benefit of icodextrin were not collected in this study. Thus, underlying mechanism(s) responsible for the decreased mortality remain speculative. Achievement of adequate ultrafiltration is an important therapeutic goal in PD patients as it impacts fluid status, blood pressure and cardiac function, which are key factors associated with morbidity and mortality [18, 19] . The importance of adequate ultrafiltation was demonstrated in the European Automated Peritoneal Dialysis Outcome Study (EAPOS), which showed that a peritoneal ultrafiltration volume >750 mL/day was associated with a significantly higher survival in anuric APD patients [20] . It is well known that icodextrin solution improves fluid management in PD patients [2] , particularly in patients with UF [6] [7] [8] . Therefore, it can be presumed that the survival advantage of icodextrin solution observed in this study is, at least partly, attributable to an improved volume control, although data on ultrafiltration and fluid status were not available in this study. Alternatively, the survival benefit of icodextrin solution could be partly explained by better preservation of residual renal function (RRF), a powerful determinant of patient outcomes in ESRD patients. This possibility was first suggested by Davies et al. [2] showing that residual urine volume was better preserved in patients using icodextrin. In addition, Adachi et al. [21] observed a similar finding in a retrospective study involving 22 APD patients. However, Konings et al. [22] raised concerns about a faster decline in RRF induced by icodextrin, possibly due to underhydration caused by excessive ultrafiltration. Other, systemic as well as local, i.e. peritoneal, benefits of icodextrin, including a higher degree of biocompatibility with respect to osmolality, absence of glucose and GDPs [3] and favourable metabolic effects [9, 10] might also have contributed to the superior outcome.
In this study, icodextrin use was significantly associated with a lower risk of technique failure. This finding is not new as several previous studies showed that icodextrin use extends PD technique survival [6] [7] [8] . However, in these studies, most patients were suffering from fluid overload. Thus, the likely reason for the beneficial outcome was attributed to an improved ultrafiltration. In contrast, our study revealed that the technique failure rate due to UF was not different between the two groups. Such discrepant findings may be explained by different characteristics of the study populations, including duration of PD and prevalence of peritoneal membrane dysfunction. It is well known that incidence of UF increases with time on PD treatment [23] . In the present study, only incident patients with a mean follow-up duration of 23.7 AE 12.4 months (range 3.1-50.3) were included. Therefore, UF would be expected to occur less frequently in our study population.
It is uncertain why dropout related to non-compliance was significantly lower in patients using icodextrin in this study. Due to the retrospective nature of this study, we could not obtain detailed information regarding the indication for the use of icodextrin. Commonly, icodextrin is used as an alternative osmotic agent to glucose for the long dwell in patients undergoing PD. Due to a concomitant increase in ultrafiltration, it reduces the need for an additional exchange procedure during daytime or nighttime, thus providing an enhanced level of convenience for patients requiring an increase in fluid removal. Moreover, in Korea, icodextrin is commonly used even in incident PD patients from the initiation of PD in order to minimize peritoneal glucose exposure, and hopefully to preserve RRF, which, regardless of indication, likely results in a more adequate fluid status, reducing the need for additional exchanges. This may provide an explanation for the lower dropout rate as well as the improved survival in the icodextrin group observed in our study.
In our previous study [15] , a multivariate Cox regression analysis showed a statistically significant lower mortality risk in patients using a physiologic pH, bicarbonate/ lactate-buffered PD solution (B/L), while the use of B/L solution in this study was associated with a statistically non-significant lower risk of death (HR, 0.72; 95% CI, 0.52-1.02; P ¼ 0.063, Table 4 ). This discrepant finding may be explained by the fact that a different subgroup of the study population was subject to the statistical analysis using PS. In the current study, the number of patients using B/L solution was lower (n ¼ 409) compared with our previous study (n ¼ 540). In addition, in the matched cohort of this study, baseline covariates were unbalanced between the B/L and conventional solution groups (data not shown). Accordingly, these different characteristics may result in lack of statistical power and the discrepant finding. Moreover, in the previous study, patients were considered as icodextrin users if they used this solution for >6 months. However, in the current study, we applied a more strict definition of 'icodextrin use', as 23.7% of the icodextrin users in the previous study utilized this solution for <50% of their PD duration. Nevertheless, whichever definition was applied, icodextrin solution use was associated with a significantly decreased risk of death.
The shortcomings of the present study include the observational and retrospective nature of study, that it is a post-hoc analysis, and the incomplete exclusion of confounding by indication. However, to minimize such unbalanced conditions, unavoidable in most observational studies, we used PS matching. Nevertheless, despite such rigorous adjustment, the interpretation of the study results should consider the fact that only the measured covariates were controlled in this analysis. Consequently, one cannot entirely exclude the possibility that unknown factors might have influenced the study results. In addition, the lack of clinical data regarding membrane transport type, ultrafiltration and other parameters to potentially explain the mechanisms responsible for the improved survival is another drawback. In particular, baseline data on RRF were missing in many patients and follow-up data on RRF were unavailable in almost all patients. Nevertheless, among 804 patients for whom data on baseline residual urine output were available, this parameter did not differ between the icodextrin and nonicodextrin groups. In addition, PD practice patterns are not entirely consistent throughout the individual centers, although most centers follow the generally recommended guidelines [24] . Finally, PD practice pattern for icodextrin should be considered because familiarity this solution may impact clinical outcomes. To clarify this concern, we compared patient and technique survival between centres that used more icodextrin and those that did not by defining the former if >30% of all PD patients were treated with this solution. However, there were no differences in patient (HR 0.85; CI, 0.63-1.14; P ¼ 0.272) or technique (HR 0.94; CI, 0.60-1.48; P ¼ 0.799) survival between these two types of centres. Presumably, an effect of centre experience may explain this finding because patients treated in less experienced center (i.e. a center that had fewer than 40 PD patients) was associated with an increased risk of all-cause mortality and technique failure (Table 4 ). In addition, practice pattern for icodextrin solution was not related to the centre experience (data not shown). These findings suggest that centre experience rather than icodextrin experience may be a more important factor affecting clinical outcomes.
In conclusion, this study provides further support to the earlier findings of a significant, positive effect of icodextrin solution on patient and technique survival. Despite the limitations of an observational study of this nature, the results of this study that are based on robustly and rigorously adjusted analyses should encourage the initiation of an adequately powered randomized, prospective trial as well as studies exploring the mechanisms underlying survival benefits associated with icdoextrin use. Conflict of interest statement. None declared.
